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Background: Hepatitis B virus (HBV) infection poses a serious threat to human health, with China being one of the
highly affected countries. However, the pathogenesis of chronic hepatitis B (CHB) is still unclear. Apolipoprotein A1
(ApoA1) which represents the major protein component of high-density lipoprotein is normally secreted by hepatocytes.
When hepatocytes are infected with HBV may lead to the disruption of ApoA1 secretion. In this study, we investigated
the effect of HBV on ApoA1 expression and preliminarily explored its molecular mechanism of regulation for revealing
the pathogenesis of CHB.
Methods: The expression of mRNA and protein of ApoA1 in Human HepG2 hepatoblastoma cells and subline
HepG2.2.15 cells were performed by reverse transcription-polymerase chain reaction (RT-PCR) and Western-blot. The
serum ApoA1, by the immune turbidimetric test, and high-density lipoprotein cholesterol (HDL-C) in CHB patients and
healthy controls, based on the enzymatic method, were measured with autobiochemical analyzer. The statistical
difference was analyzed by SPSS 13.0. HBV infectious clone, pHBV1.3, and ApoA1 gene promoter were co-transfected
into HepG2, and the luciferase activity was determined. The changes of ApoA1 mRNA and protein expression were
detected by RT-PCR and Western-blot method, after HepG2 cells were transfected with pHBV1.3.
Results: The expression of ApoA1 mRNA and protein in HepG2.2.15 were lower than those in HepG2, and when
compared with healthy controls, serum levels of ApoA1 and HDL-C in CHB patients were lower (P < 0.05). pHBV1.3
in HepG2 cells restrained the activity of ApoA1 promoter, mRNA and protein expression.
Conclusions: HBV could inhibit the expression of ApoA1 in vitro and in vivo.
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Hepatitis B virus (HBV) infection has a devastating effect
on human health. According to statistics, there are about
3 billion people with HBV infection in the whole world.
China is one of the highly affected countries in the world;
approximately 120 million people are carrying HBV, and
about a quarter of HBV patients develop chronic hepatitis
disease, including chronic hepatitis, liver fibrosis, liver cir-
rhosis and liver cancer [1]. So far, the pathogenesis of
CHB remains unclear. In a previous study, we explored
the pathogenesis of CHB by screening the differential
expression genes between the hepatocellular carcinoma
cell line HepG2 and HepG2.2.15 cell lines (integrated the
HBV genome) by gene chip and found that the expression* Correspondence: windflower6174@gmail.com
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Apoliprotein A1 (ApoA1) which represents the major
protein component of high-density lipoprotein is normally
secreted by hepatocytes. When hepatocytes are infected
with HBV may lead to the disruption of ApoA1 secretion.
An inverse correlation between HBV and ApoA1 was
found in two hepatoma cell lines [3]. Plasma ApoA1 was
decreased in chronic hepatitis B patients [4]. The current
research is mainly to study the effect of HBV on ApoA1
expression, and preliminarily explore its molecular
mechanism of regulation as a basis for revealing the
pathogenesis of chronic hepatitis.Materials and methods
Experiment design
Our experiment is mainly divided into two parts. First,
plasma ApoA1 was investigated in CHB patients andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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HBV and ApoA1, considering that ApoA1 is normally
secreted by hepatocytes. Then a cell-cuture experiment
was performed to illuminate whether ApoA1 expression
could be influenced by HBV.
Study subjects
The study recruited 118 clinically diagnosed chronic
hepatitis B (CHB) patients from Union Hospital, Tongji
Medical College, Huazhong University of Science and
Technology, including 66 males and 52 females. All sub-
jects were Chinese Han ethnic origin and from the Central
China. All subjects were given Informed Consent Forms
and the study protocols were approved by the Hospital
Ethics Committee. The mean age was 46.3 ± 15.4 years.
Case selection was consistent with the diagnostic criteria
of “viral hepatitis prevention and treatment measure”
which were jointly revised by the Infectious and Parasitic
diseases branch and Hepatology of the Chinese Medical
Association in 2000. The patients who had a history of
critical organs disease such as heart, brain and kidney
disease or other chronic liver disease were excluded.
Another 102 healthy subjects (57 males and 45 females)
were selected as controls, the mean age was 43.7 ±
14.5 years. There was no statistical difference between
the gender, age and height of CHB patients and healthy
controls (P > 0.05).
Materials
Human hepatoma cell lines, HepG2 and HepG2.2.15,
were provided by Central Laboratory, Union Hospital,
Tongji Medical College, Huazhong University of Science
and Technology. HBV infectious clone, pHBV1.3 (Genbank
number: U95551), was constructed by our laboratory.
Liposomal transfection (lipofectamine 2000) and RNA
extraction reagents (TRIzolR) were purchased from
Invitrogen Company, and M-MLV reverse transcriptase
was purchased from Promega Corporation (America).
ApoA1 monoclonal antibody was purchased from Shanghai
Gaochuang Chemical Technology Co., Ltd.
Methods
1. ApoA1 and HDL-C detection: ApoA1, by the immune
turbidimetric test, and HDL-C, based on the enzymatic
method, were measured by Olympus 5400 automatic
biochemical analyzer.
2. Cell culture and transfection:Human HepG2
hepatoblastoma cells and subline HepG2.2.15 cells
were cultured in the RPMI-1640 medium containing
10% fetal bovine serum, 100 U/mL penicillin and
100 mg/L streptomycin, in 37°C incubator with 5%
volume fraction of CO2. Before transfection, HepG2
cells were seeded in 6-well plates. The transfectionmethod was as follows, different doses of plasmids
and lipofectamine 2000 transfection reagents were
diluted in 100 μL RPMI-1640 medium without
serum and double-antibody, at room temperature
for 20 minutes, the prepared transfection solution
was added to the medium of HepG2 cells and
cultured in the CO2 incubator.
3. RNA isolation and cDNA synthesis: Total RNA was
isolated using RNA purification columns (Qiagen).
cDNA was synthesized using cDNA Synthesis Kit
(Qiagen) with the primer as T7-Oligo (dT) 15(5’-AA
ACGACGGCCA GTGAATTGTAATACGACTC
ACTATAGGCGCTTTTTTTTTTTTTTTTV-3’ , V
might be G, C and A). cRNA was synthesized using
T7 RiboMAX Express Large Scale RNA Production
System (Promega). cRNA was reverse transcribed
with M-MLV reverse transcriptase (Invitrogen). The
products of cRNA reverse transcription were labeled
with KLENOW enzyme. The final concentrations of
dATP, dGTP and dTTP were all 120 μmol/L, the
final concentration of dCTP was 60 μmol/L, and the
final concentrations of Cy5-dCTP and Cy3-dCTP
were both 40 μmol/L.
4. cDNA microarray hybridization and analysis:
Purified, labeled cDNA was hybridized in 30 μl of
hybridization buffer (25% formamide, 3 × SSC, 0.2%
SDS) at 42°C for a whole night. After incubation, the
slides were washed and scanned in a LuxScan 10KA
scanner (CapitalBio Company, Beijing, China).
5. RT-PCR: This was performed using TRIzolR reagent.
Total RNA was extracted from cells and cDNA was
synthesized by reverse transcription. ApoA1 gene
was amplified by PCR with the forward primer
5'-ATGAAAGCTGCGGTGCTGA-3' and the
reverse primer 5'-TCACTGGGTGTTGAGCTTC-3',
β-actin was chosen as an internal reference. The
final products were analyzed by 1% agarose gel
electrophoresis.
6. Determination of luciferase: HepG2 cells were
cultured for 48 h after transfection, the supernatant
was removed and the cells were washed by PBS. A cell
lysis buffer was added to lyse the cells. When the cells
were completely lysed, 50 μL cells lysate and 50 μL
luciferin substrate were added to it. The optical
density was then measured using a Luminometer.
7. Western-blot: HepG2 cells were lysed by
ultrasonication, and proteins in the supernatant
were extracted after centrifugation. The protein
concentration was determined by coomassie
brilliant blue G250 method. 30 μg of sample
proteins and an equal volume of loading buffer were
subjected to 12% SDS-PAGE and transferred onto
nitrocellulose (NC) membranes. The membranes
were subsequently incubated with ApoA1 monoclonal
Figure 2 Comparison of serum HDL-C levels between healthy
controls and HBV patients, *P < 0.05.
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incubation with horseradish peroxidase conjugated
goat anti-rabbit secondary antibody (1:500) for
one hour. Visualization was performed by the
electrochemical luminescence (ECL) method. Images
were digitally acquired using Kodak 4000MM image
station and densitometry was conducted using the
companion software (Carestream Molecular Imaging,
New Heaven, CT).
Statistical analysis
All data were statistically analyzed by SPSS13.0, and the
data were expressed as mean ± standard deviation. The
variances were the same (P > 0.05). Two-sample t-test
was used to evaluate the differences between the ApoA1
and HDL-C levels of CHB patients and controls. P value
of less than 0.05 was considered statistically significant.
Results
The serum ApoA1 and HDL-C levels of patients with HBV
infection
ApoA1 levels in healthy controls (1.37 ± 0.19 g/L) were
higher than that in HBV patients (0.86 ± 0.34 g/L, P < 0.05;
see Figure 1). HDL-C in HBV patients (1.44 ± 0.56 mol/L)
was significantly lower than that in healthy controls
(1.71 ± 0.34 mmol/L, P < 0.05; see Figure 2).
HBV suppression of ApoA1 mRNA and protein expression
We screened the differential expression genes between
HepG2 and HepG2.2.15 cells by gene chip technology.
As a result, cy3/cy5 (R/G value), the fluorescence intensity
of ApoA1 in HepG2.2.15 and HepG2 cells was 0.0514
which showed that there were significant differences
between the expression of ApoA1 in HepG2.2.15 and
in HepG2 cells, and the transcription in HepG2.2.15
cells decreased (see Figure 3).
We confirmed the result of gene chip by RT-PCR and
Western-blot, the results showed that the expression ofFigure 1 Comparison of serum ApoA1 levels between healthy
controls and HBV patients, *P < 0.05.ApoA1 mRNA and protein in HepG2 was significantly
higher than those in HepG2.2.15 (P < 0.001, see Figures 4
and 5).
These results suggested that HBV could downregulate
the expression of ApoA1 mRNA and protein in cells.
HBV inhibition of ApoA1 promoter activity
Different doses of HBV infectious clone pHBV1.3 (0 μg,
0.5 μg, 1 μg, 2 μg) with ApoA1 promoter pApoA1-Luc
co-transfected into HepG2 cells, with pBlue-ks as blank
control. The results of luciferase activity exhibited that the
activity of ApoA1 promoter decreased with the increasing
content of pHBV1.3 (0 μg, 0.5 μg, 1 μg, 2 μg), this were
1205.62 ± 43.14RUL/μg, 792.77 ± 37.27RUL/μg, 496.59 ±
26.31RUL/μg and 229.42 ± 16.49RUL/μg respectively
(P < 0.001, see Figure 6).
HBV inhibition of the expression of ApoA1 mRNA and
protein
Different doses of HBV infectious clone pHBV1.3 (0 μg,
0.5 μg, 1 μg, 2 μg) were transfected into HepG2 cells.
The changes of ApoA1 mRNA and protein expression
were detected by RT-PCR and Western-blot. As a result,
transfection with increasing content of pHBV1.3, the
expression of ApoA1 mRNA and protein continued to
reduce, in a dose-dependent effect (see Figures 7 and 8).
Discussion
At present, it is generally considered that liver cells
damage is not directly associated with CHB pathogen-
esis, but caused by inflammatory reaction and immune
response of the body after HBV infection [5]. Studies
showed that HBV infection could regulate the changes
of numerous protein expression, including interleukins
27 (IL-27), IL-29, IL-8 and cyclooxygenase (COX-2),
etc. [2,6].
Figure 3 Exchange images of two kinds of fluorescences of HepG2 vs HepG2.2.15.
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stably transfected with the HBV genome, and can ex-
press viral RNA and protein, synthetise and secrete the
complete virus-like particles. To further explore the
pathogenesis of CHB, differential expression genes in
HepG2.2.15 and HepG2 cells were screened by gene
chip, a series of differentially expressed proteins were
found, such as ApoA1. A previous research results in-
dicated that HBV inhibited the synthesis and secretion
of ApoB by the regulation of microsomal triglyceride
transfer protein (MTP) expression [7].Figure 4 HBV suppression of ApoA1 mRNA expression. ApoA1
mRNA expression between HepG2 and HepG2.2.15 cells was
measured by RT-PCR. Representative images are shown in A and
quantification data in B. M represents Marker. **P < 0.001.Gene chip technology has the characteristics of high flux
and high sensitivity, but there are certain false positive and
false negative at the same time. We confirmed the result of
gene chip by RT-PCR and Western-blot. Many studies have
shown that the level of circulating ApoA1 correlates with
CHB and CHB related disease [3,8-10]. Our results sug-
gested HBV inhibited the expression of ApoA1 mRNA andFigure 5 HBV suppression of ApoA1 protein expression. ApoA1
protein expression between HepG2 and HepG2.2.15 cells was measured
by western-blot. Representative images are shown in A and
quantification data in B. **P < 0.001.
Figure 6 Effect of different doses of pHBV1.3 on the activity of ApoA1 promoter in HepG2 cells, **P < 0.001.
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CHB patients and healthy controls. The decrease of serum
ApoA1 levels indicated that HBV could inhibit the expres-
sion of ApoA1 mRNA and protein in vitro. ApoA1 is the
carrier of free cholesterol in vivo, and the major structuralFigure 7 HBV inhibition of the expression of ApoA1 mRNA. The
expression of ApoA1 mRNA in HepG2 cells inhibited by different
doses of pHBV1.3 was measured by RT-PCR. Representative images
are shown in A and quantification data in B. Data were considered
significant if P < 0.05(indicated by “*”) and P < 0.001(indicated
by “**”).protein of HDL-C. The serological level of HDL-C in these
two groups was further tested. The serum levels of HDL-C
in CHB patients were lower than that in the healthy
controls, which demonstrated that HBV affected the serum
HDL-C levels by inhibiting the expression of ApoA1.Figure 8 HBV inhibition of the expression of ApoA1 protein.
The expression of ApoA1 protein in HepG2 cells inhibited by different
doses of pHBV1.3 was measured by western-blot. Representative
images are shown in A and quantification data in B. Data were
considered significant if P < 0.05(indicated by “*”) and P < 0.001
(indicated by “**”).
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sion regulated by HBV, we achieved ApoA1 promoter
(−474 + 7) by PCR amplification, cloned it to pGL3-basic
vector with luciferase reporter gene and constructed
ApoA1 promoter luciferase reporter gene pApoA1-Luc
[11]. The regulation of HBV on ApoA1 promoter was
measured with fluorescent reporter gene system, and the
change of ApoA1 mRNA and protein expression was
detected by RT-PCR and Western-blot. ApoA1 expression
in promoter, mRNA and protein levels, were inhibited by
HBV, in a dose-dependent effect. All these indicated that
HBV was likely to down regulate the activity of ApoA1
promoter to inhibit ApoA1 mRNA and protein expres-
sion. However, the signal pathway of the regulation of
HBV on ApoA1 expression and its exact mechanism
remained unknown.
A number of studies had shown that viral infections
could cause the disorder of lipoprotein metabolism
in vivo, such as ApoA1, ApoB, HDL-C, low density lipo-
protein cholesterol (LDL-C), total triglyceride (TG) and
other apolipoproteins, and lipoprotein levels in serum
were reduced after heptatitis C virus (HCV) infection
[12-14]. In other studies, an inverse correlation between
HBV and ApoA1 was found in two hepatoma cell lines
[3] and plasma ApoA1 was decreased in chronic hepatitis
B patients [4]. Consistent with these findings, in our
research, we investigated the effect of HBV on ApoA1 ex-
pression, and found out that HBV inhibited the synthesis
and secretion of ApoA1 and HDL-C at the same time.
HBV infection could cause acute or chronic inflammation
of the body and studies have confirmed the anti-
inflammatory effect of HDL-C [15]. HBV might suppress
the synthesis and secretion of HDL-C by inhibiting
ApoA1 expression, and then promote the inflammatory
response. Information from previous research of HBV
effect on ApoB expression and this current research make
it clear that HBV infection can also lead to the disorders
of lipid metabolism. However, whether HBV infection as
well as HCV infection is able to cause liver steatosis
remains unclear.
Conclusions
In conclusion, this study explored the HBV regulation for
ApoA1 from the perspectives of clinical and cellular levels
which revealed the pathogenesis of CHB and provided the
theoretical basis for clinical diagnosis and treatment of
CHB.
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